SCOTTSDALE, Ariz. — June 9, 2011 — TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced today.
"The highest quality medical imaging provided by Imaging Endpoints is one more weapon in TD2's arsenal," said Dr. Stephen Gately, President of TD2, which assists drug developers in navigating the regulatory maze involved in the successful completion of clinical trials and bringing new therapeutics to market. "Our relationship is meant to help combine the best available technologies."
Imaging Endpoints will assist TD2 in the design and implementation of medical imaging analyses. Imaging Endpoints' expertise in anatomic and functional imaging will allow drug developers to best incorporate imaging into their clinical trials: probing molecular drug targets, assessing biologic responses and evaluating drug effectiveness.
"We hope that, through our new relationship with TD2, we will be able to assist oncology drug developers to maximize their return on investment in medical imaging during the course of their early-phase clinical trials," said Ron Korn, Medical Director of Imaging Endpoints. "Significant resources and time can be saved through wise and appropriate implementation of medical imaging."
The rapid completion of often time-consuming and costly clinical trials is needed to speed new treatments to the patients who need them, Dr. Gately said.
Scottsdale Mayor Jim Lane hailed the announcement by TD2 and Imaging Endpoints: "The partnership announced today between TD2 and Imaging Endpoints represents the merging of talents between two premier Scottsdale companies, and helps cement TD2 as a cornerstone of Scottsdale's growing biomedical industry."
Imaging holds the potential to predict outcomes, shorten the time needed to evaluate if a drug is hitting its target, and do so with relatively low risk to patients. By using specific imaging techniques, researchers can assess if new drug compounds are effective in such areas as anti-proliferation, metabolism and hypoxia.
About Imaging Endpoints:
Imaging Endpoints is a full-service imaging contract research organization providing services to the pharmaceutical and medical device industries to accelerate their national and international oncology clinical trials. Extensive expertise in Cancer Imaging allows Imaging Endpoints to perform qualitative and quantitative assessments of both anatomic and physiologic/metabolic imaging modalities in order to better probe the effectiveness of new therapeutics. In addition to oncology, Imaging Endpoints has expertise in cardiovascular, neurological and musculoskeletal radiologic sciences, and experience in all phases of clinical trials, from preclinical through post-market. For more information about our suite of services, please visit www.imagingendpoints.com.
Press Contact:
Alison Coates
Director
480-314-3070
acoates@imagingendpoints.com
About TD2
TGen Drug Development (TD2), a wholly owned subsidiary of the Translational Genomics Research Institute (TGen), is a 501(c) 3 non-profit organization. TD2 provides innovative services for oncology focused biopharmaceutical companies using a dedicated team of professionals with broad experience and understanding in drug development. TD2 is uniquely positioned to support the need for improved and accelerated development of new chemical entities (NCE's) for life-threatening diseases. TD2 uses a unique combination of experience gained through its contract research organization business, and an integrated suite of proprietary and non-proprietary tools, preclinical study execution, regulatory affairs assistance, clinical trial design and management, and drug development experts to successfully move therapeutics towards regulatory approval. TD2 is dedicated to reducing the risks and uncertainty inherent in the drug development process. For more information, visit www.td2.org.
About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: www.tgen.org.
Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
syozwiak@tgen.org